DEPARTMENT OF HEALTH & HUMAN SERVICES

FOR US POSTAL SERVICE DELIVERY:

Office for Human Research Protections 6100 Executive Boulevard, Suite 3B01 National Institutes of Health (MSC 7507) Rockville, Maryland 20892-7507

FOR HAND DELIVERY OR EXPRESS MAIL:

Office for Human Research Protections 6100 Executive Boulevard, Suite 3B01 Rockville, Maryland 20852

> Telephone: 301-435-8072 FAX: 301-402-2071 E-mail: borrork@od.nih.gov

September 21, 2001

Bruce G. Lindsey, Ph.D. Interim Vice President for Research University of South Florida 4202 E. Fowler Avenue, ADM 200 Tampa, FL 33620-5950.

J. Thomas Danzi, Sr., M.D. Vice President and Chief Medical Officer Tampa General Healthcare P.O. Box 1289 Tampa, FL 33601

RE: Human Research Subject Protections Under Multiple Project Assurance (MPA) M-1284

Research Project: An Ascending Dose Safety and Feasibility Study of OSSIGEL in the Management of Stable and Unstable Closed Diaphyseal Fractures of the Tibia Principal Investigator: Roy W. Sanders, MD Project Number: 5194

Dear Dr. Lindsey and Dr. Danzi:

The Office for Human Research Protections (OHRP) has reviewed your report of August 28, 2001, regarding the above referenced research conducted at Tampa General Healthcare, which has an inter-institutional amendment with University of South Florida (USF).

Based upon its review, OHRP finds that the corrective actions taken by USF adequately address the previous findings, questions and concerns outlined by OHRP and are appropriate under the USF Multiple Project Assurance (MPA). As a result, OHRP is closing this case and there should be no need for further involvement of OHRP in this matter. Of course, OHRP must be notified should new information be identified which might alter this determination.

Page 2 of 2 M-1284 September 21, 2001

OHRP appreciates your institution's continued commitment to the protection of human research subjects. Do not hesitate to contact me if you have any questions regarding this matter.

Sincerely,

Kristina C. Borror, Ph.D. Compliance Oversight Coordinator Division of Compliance Oversight

cc: Dr. Barry B. Bercu, Chair, USF IRB 01, 01b, and 02

Dr. Martin Klemperer, Chair, USF IRB 03

Dr. Ramon Lopez del Valle, Chair, USF IRB 04

Dr. Roy Sanders, Tampa General Healthcare

Commissioner, FDA

Dr. David Lepay, FDA

Dr. James F. McCormack, FDA

Dr. John Mather, VA

Dr. Greg Koski, OHRP

Dr. Melody H. Lin, OHRP

Dr. Michael A. Carome, OHRP

Dr. Jeffrey M. Cohen, OHRP

Mr. George Gasparis, OHRP

Mr. Barry Bowman, OHRP